Merus

MRUS

Market cap $7.19B

- Petosemtamab in combination with FOLFOX /FOLFIRI (1L and 2L mCRC) and as monotherapy (3L+ mCRC), demonstrates antitumor activity and a manageable safety profile

-   Plenary session oral presentation: Friday, October 24 10:00 -11:40 a.m. ET -   Poster presentation on preclinical evaluation of petosemtamab on cancer stem cells: Friday, October 24 12:30-4:00 p.m.

NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Merus N.V. (NasdaqGM: MRUS) to Genmab A/S (NasdaqGS: GMAB). Under the terms of the proposed transaction, shareholders of Merus will receive $97.00 in cash for each share of Merus that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whe.

NEW YORK , Sept. 30, 2025 /PRNewswire/ --  Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.

Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction representing a transaction value of approximately $8 billion.

Genmab, on Monday, announced its plan to buy Merus for about $8 billion. The news sent Merus stock into the stratosphere.

Genmab will acquire Merus in an all-cash transaction worth around $8 billion.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Merus N.V. (NASDAQ: MRUS) to Genmab A/S for $97.00 per share is fair to Merus shareholders. Halper Sadeh encourages Merus shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Merus and its board of directors violate.

Merus agreed to be bought for a 41% premium, months after a positive trial of a cancer drug.